Agios Pharmaceuticals
(NASDAQ:AGIO)
$30.21
0[0.00%]
At close: Apr 22
$30.21
0[0.00%]
PreMarket: 4:00PM EDT
Q1 2024 Earnings in 9 days from now on Thu May 2nd, before the market open
Consensus Rating1
Buy
Highest Price Target1
$0.00
Lowest Price Target1
$0.00
Consensus Price Target1
$39.92

Agios Pharmaceuticals Stock (NASDAQ:AGIO), Analyst Ratings, Price Targets, Predictions

Agios Pharmaceuticals Inc has a consensus price target of $39.92, established from looking at the 28 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, JP Morgan, and RBC Capital on April 9, 2024, February 23, 2024, and February 16, 2024. With an average price target of $24 between Cantor Fitzgerald, JP Morgan, and RBC Capital, there's an implied -20.56% downside for Agios Pharmaceuticals Inc from these 3 analyst ratings.

Analyst Trend
1
Nov 23
1
1
Feb
1
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Cantor Fitzgerald
JP Morgan
RBC Capital
Goldman Sachs
RBC Capital

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Agios Pharmaceuticals

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
04/09/2024AGIOBuy Now
Agios Pharmaceuticals
$30.21Cantor Fitzgerald
Eric Schmidt
Reiterates → OverweightGet Alert
02/23/2024AGIOBuy Now
Agios Pharmaceuticals
$30.21-0.7%JP Morgan
Tessa Romero
$31 → $30MaintainsNeutralGet Alert
02/16/2024AGIOBuy Now
Agios Pharmaceuticals
$30.2139.03%RBC Capital
Gregory Renza
$43 → $42MaintainsOutperformGet Alert
11/03/2023AGIOBuy Now
Agios Pharmaceuticals
$30.21-7.32%Goldman Sachs
Salveen Richter
$32 → $28MaintainsNeutralGet Alert
08/07/2023AGIOBuy Now
Agios Pharmaceuticals
$30.215.93%JP Morgan
Tessa Romero
$33 → $32MaintainsNeutralGet Alert
06/27/2023AGIOBuy Now
Agios Pharmaceuticals
$30.2139.03%RBC Capital
Kennen MacKay
$40 → $42MaintainsOutperformGet Alert
02/03/2023AGIOBuy Now
Agios Pharmaceuticals
$30.2135.72%Piper Sandler
Christopher Raymond
→ $41Initiates → OverweightGet Alert
12/01/2022AGIOBuy Now
Agios Pharmaceuticals
$30.219.24%JP Morgan
Tessa Romero
$48 → $33MaintainsNeutralGet Alert
11/17/2022AGIOBuy Now
Agios Pharmaceuticals
$30.215.93%Goldman Sachs
Salveen Richter
$17 → $32UpgradeSell → NeutralGet Alert
08/05/2022AGIOBuy Now
Agios Pharmaceuticals
$30.2122.48%SVB Leerink
Andrew Berens
$33 → $37MaintainsOutperformGet Alert
07/27/2022AGIOBuy Now
Agios Pharmaceuticals
$30.219.24%SVB Leerink
Andrew Berens
→ $33UpgradeMarket Perform → OutperformGet Alert
05/24/2022AGIOBuy Now
Agios Pharmaceuticals
$30.21-47.04%Goldman Sachs
Salveen Richter
$20 → $16MaintainsSellGet Alert
05/17/2022AGIOBuy Now
Agios Pharmaceuticals
$30.219.24%SVB Leerink
Andrew Berens
$30 → $33MaintainsMarket PerformGet Alert
03/07/2022AGIOBuy Now
Agios Pharmaceuticals
$30.21-23.87%Goldman Sachs
Salveen Richter
$37 → $23MaintainsSellGet Alert
03/03/2022AGIOBuy Now
Agios Pharmaceuticals
$30.21217.78%HC Wainwright & Co.
Michael King
$98 → $96MaintainsBuyGet Alert
02/25/2022AGIOBuy Now
Agios Pharmaceuticals
$30.21121.78%RBC Capital
Kennen MacKay
$61 → $67MaintainsOutperformGet Alert
02/24/2022AGIOBuy Now
Agios Pharmaceuticals
$30.21217.78%HC Wainwright & Co.
Michael King
$98 → $96MaintainsBuyGet Alert
02/22/2022AGIOBuy Now
Agios Pharmaceuticals
$30.21-0.7%SVB Leerink
Andrew Berens
$32 → $30MaintainsMarket PerformGet Alert
02/18/2022AGIOBuy Now
Agios Pharmaceuticals
$30.21224.4%HC Wainwright & Co.
Michael King
$95 → $98MaintainsBuyGet Alert

FAQ

Q

What is the target price for Agios Pharmaceuticals (AGIO)?

A

The latest price target for Agios Pharmaceuticals (NASDAQ: AGIO) was reported by Cantor Fitzgerald on April 9, 2024. The analyst firm set a price target for $0.00 expecting AGIO to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Agios Pharmaceuticals (AGIO)?

A

The latest analyst rating for Agios Pharmaceuticals (NASDAQ: AGIO) was provided by Cantor Fitzgerald, and Agios Pharmaceuticals reiterated their overweight rating.

Q

When was the last upgrade for Agios Pharmaceuticals (AGIO)?

A

The last upgrade for Agios Pharmaceuticals Inc happened on November 17, 2022 when Goldman Sachs raised their price target to $32. Goldman Sachs previously had a sell for Agios Pharmaceuticals Inc.

Q

When was the last downgrade for Agios Pharmaceuticals (AGIO)?

A

The last downgrade for Agios Pharmaceuticals Inc happened on July 30, 2021 when Goldman Sachs changed their price target from $58 to $39 for Agios Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Agios Pharmaceuticals (AGIO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Agios Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Agios Pharmaceuticals was filed on April 9, 2024 so you should expect the next rating to be made available sometime around April 9, 2025.

Q

Is the Analyst Rating Agios Pharmaceuticals (AGIO) correct?

A

While ratings are subjective and will change, the latest Agios Pharmaceuticals (AGIO) rating was a reiterated with a price target of $0.00 to $0.00. The current price Agios Pharmaceuticals (AGIO) is trading at is $30.21, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch